SMMT
Summit Therapeutics Inc.
NASDAQ · USHealthcareBiotechnology
$13.50-2.24%
Price as of Jul 20, 2026
SMMT financials
Summit Therapeutics Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $583.2K |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $583.2K |
| Operating expenses | $1.1B | $180.5M | $478.2M | $60.2M |
| Operating income | -$1.1B | -$180.5M | -$478.2M | -$59.6M |
| Net income | -$1.1B | -$176.8M | -$482.4M | -$65.2M |
| EBITDA | -$1.1B | -$168.5M | -$69.5M | -$51.6M |
| Basic EPS | $-1.44 | $-0.25 | $-0.78 | $-0.34 |
| Diluted EPS | $-1.44 | $-0.25 | $-0.78 | $-0.34 |
| Balance sheet | ||||
| Cash & equivalents | $167.2M | $83.8M | $56.5M | $284.2M |
| Total assets | $557.5M | $348.1M | $160.6M | $541.4M |
| Total liabilities | $68.5M | $37.4M | $99.1M | $438.2M |
| Stockholders’ equity | $489.0M | $310.6M | $61.5M | $103.2M |
| Total debt | $15.5M | $5.8M | $84.0M | $422.9M |
| Net debt | -$151.7M | -$78.0M | $27.4M | $138.7M |
| Cash flow | ||||
| Operating cash flow | -$239.7M | -$113.6M | -$60.7M | -$33.9M |
| Capital expenditure | -$487.6K | -$111.1K | -$101.3K | -$508.7K |
| Free cash flow | -$240.2M | -$113.7M | -$60.8M | -$34.4M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |